Evidence map›Paper›PMID 38856808›Full record

SynthesisInfection2024

Clinical characteristics and outcomes in pseudomonas endocarditis: a systematic review of individual cases : Systematic review of pseudomonas endocarditis.

Durga Shankar Meena, Deepak Kumar, Bhuvanesh Kumar, Gopal Krishana Bohra, Naresh Midha, Mahendra Kumar Garg

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Infection, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Newly recognized typical microorganisms in intracardiac prosthetic material-related infective endocarditis: evidence behind their inclusion in the 2023 Duke-ISCVID criteria.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Durga Shankar MeenaDivision of Infectious Diseases, Department of Internal Medicine, All India Institute of Medical Sciences, Jodhpur, 342005, India. dsmims14@gmail.com.ORCID https://orcid.org/0000-0001-9524-5278
Deepak KumarDivision of Infectious Diseases, Department of Internal Medicine, All India Institute of Medical Sciences, Jodhpur, 342005, India.
Bhuvanesh KumarDivision of Infectious Diseases, Department of Internal Medicine, All India Institute of Medical Sciences, Jodhpur, 342005, India.
Gopal Krishana BohraDivision of Infectious Diseases, Department of Internal Medicine, All India Institute of Medical Sciences, Jodhpur, 342005, India.
Naresh MidhaDivision of Infectious Diseases, Department of Internal Medicine, All India Institute of Medical Sciences, Jodhpur, 342005, India.
Mahendra Kumar GargDivision of Infectious Diseases, Department of Internal Medicine, All India Institute of Medical Sciences, Jodhpur, 342005, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe landscape of Pseudomonas infective endocarditis (IE) is evolving with the widespread use of cardiac implantable devices and hospital-acquired infections. This systematic review aimed to evaluate the emerging risk factors and outcomes in Pseudomonas IE.

methodsA literature search was performed in major electronic databases (PubMed, Scopus, and Google Scholar) with appropriate keywords and combinations till November 2023. We recorded data for risk factors, diagnostic and treatment modalities. This study is registered with PROSPERO, CRD42023442807.

resultsA total of 218 cases (131 articles) were included. Intravenous drug use (IDUs) and prosthetic valve endocarditis (PVE) were major risk factors for IE (37.6% and 22%). However, the prosthetic valve was the predominant risk factor in the last two decades (23.5%). Paravalvular complications (paravalvular leak, abscess, or pseudoaneurysm) were described in 40 cases (18%), and the vast majority belonged to the aortic valve (70%). The mean time from symptom onset to presentation was 14 days. The incidence of difficult-to-treat resistant (DTR) pseudomonas was 7.4%. Valve replacement was performed in 57.3% of cases. Combination antibiotics were used in most cases (77%), with the aminoglycosides-based combination being the most frequently used (66%). The overall mortality rate was 26.1%. The recurrence rate was 11.2%. Almost half of these patients were IDUs (47%), and most had aortic valve endocarditis (76%).

conclusionsThis review highlights the changing epidemiology of Pseudomonas endocarditis with the emergence of prosthetic valve infections. Acute presentation and associated high mortality are characteristic of Pseudomonas IE and require aggressive diagnostic and therapeutic approach.

Indexed as

Anti-Bacterial AgentsEndocarditis, BacterialPseudomonas InfectionsHumansPseudomonasRisk FactorsAnti-Bacterial AgentsCombination therapyGram-negative bacilliInfective endocarditisProsthetic valvePseudomonas aeruginosa

Identifiers

PMID38856808

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.